Comparative Study
doi: 10.1097/IAE.0b013e31815e9322.
Avastin versus Lucentis: ethical issues in treatment of age-related macular degeneration
- PMID: 18046218
- DOI: 10.1097/IAE.0b013e31815e9322
Item in Clipboard
Comparative Study
Avastin versus Lucentis: ethical issues in treatment of age-related macular degeneration
Retina.
2007 Nov-Dec.
No abstract available
Comment in
-
Cheap shots and pricey propositions: evidence, disclosure, and treatment of age-related macular degeneration.Retina. 2007 Nov-Dec;27(9):1166-7. doi: 10.1097/IAE.0b013e31815ee57e. Retina. 2007. PMID: 18046219 No abstract available.
-
Avastin versus Lucentis: ethical issues.Retina. 2008 Jul-Aug;28(7):1024-5; author reply 1025. doi: 10.1097/IAE.0b013e318176de5f. Retina. 2008. PMID: 18698312 No abstract available.
Similar articles
-
Avastin versus Lucentis: ethical issues.Retina. 2008 Jul-Aug;28(7):1024-5; author reply 1025. doi: 10.1097/IAE.0b013e318176de5f. Retina. 2008. PMID: 18698312 No abstract available.
-
Cheap shots and pricey propositions: evidence, disclosure, and treatment of age-related macular degeneration.Retina. 2007 Nov-Dec;27(9):1166-7. doi: 10.1097/IAE.0b013e31815ee57e. Retina. 2007. PMID: 18046219 No abstract available.
-
Position paper: the need for head-to-head studies comparing Avastin versus Lucentis.Surv Ophthalmol. 2009 Nov-Dec;54(6):705-7. doi: 10.1016/j.survophthal.2009.08.002. Surv Ophthalmol. 2009. PMID: 19818262 Review. No abstract available.
-
Intravitreal avastin: the low cost alternative to lucentis?Am J Ophthalmol. 2006 Jul;142(1):141-3. doi: 10.1016/j.ajo.2006.03.036. Am J Ophthalmol. 2006. PMID: 16815262 No abstract available.
-
Avastin and new treatments for AMD: where are we?Retina. 2006 Oct;26(8):853-8. doi: 10.1097/01.iae.0000244722.35073.7c. Retina. 2006. PMID: 17031283 Review. No abstract available.
Cited by
-
Intracellular bevacizumab reduces phagocytotic uptake in RPE cells.Graefes Arch Clin Exp Ophthalmol. 2010 Jun;248(6):819-24. doi: 10.1007/s00417-010-1317-x. Epub 2010 Feb 19. Graefes Arch Clin Exp Ophthalmol. 2010. PMID: 20169356
-
Quantifying the increasing use of anti-vascular endothelial growth factor therapy in ophthalmology.Mcgill J Med. 2011 Jun;13(1):38. Mcgill J Med. 2011. PMID: 22815647 Free PMC article.
-
Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?Drugs Aging. 2009;26(4):295-320. doi: 10.2165/00002512-200926040-00002. Drugs Aging. 2009. PMID: 19476398 Review.
-
A randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV.Graefes Arch Clin Exp Ophthalmol. 2015 Nov;253(11):1867-72. doi: 10.1007/s00417-014-2886-x. Epub 2014 Dec 13. Graefes Arch Clin Exp Ophthalmol. 2015. PMID: 25500986 Clinical Trial.
-
Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?Clin Interv Aging. 2009;4:457-61. doi: 10.2147/cia.s8367. Epub 2009 Dec 29. Clin Interv Aging. 2009. PMID: 20054410 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
